Capital Royalty

Founded 2004, Capital Royalty acquires and manages a portfolio of royalty and revenue interests in the healthcare sector. Capital Royalty invests in a broad range of healthcare market segments, including pharmaceuticals, biotechnology products, drug delivery technologies, diagnostics, medical devices and over-the-counter drugs. Capital Royalty targets investments between $20 and $300 million and focuses on products that have been approved by the appropriate regulatory authorities, and are supported by companies with dedicated sales and marketing infrastructures. Charles W. Tate, Chairman and Founding Partner, has over 30 years of private equity, merchant and investment banking experience with investment institutions such as Hicks, Muse, Tate and Furst. The firm has offices in TX, CO, and NY.